Ecopia gets notice of allowance for ECO-4601 analogs

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Ecopia BioSciences, Inc. announced that the Canadian Intellectual Property Office issued a notice of allowance for Canadian Patent Application CA 2,511,750 directed to "Dibenzodiazepinone Analogues, Processes for their Production and their Use as Pharmaceuticals."

This patent will add to Montreal-based Ecopia's intellectual property arsenal around its anticancer drug candidate ECO-4601, currently in a phase 1 clinical trial.

The pharmaceutical company said this patent is an important component of the patent estate the company has been diligently building around ECO-4601 over the past two years. The patent provides composition-of-matter protection over a large number of analogs and derivatives produced by chemical modification of ECO-4601 as well as exclusive rights over their use in pharmaceutical compositions generally and cancer-related medical uses in particular.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.